SG1906

Phase 1Small molecule

SG1906 is one of 7 small molecule programs targeting Locally Advanced Unresectable or Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Unresectable or Metastatic Solid TumorsRecruiting

Locally Advanced Unresectable or Metastatic Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Locally Advanced Unresectable or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 2

RC148

RRemeGen Co., Ltd.

Phase 2

1 3

IBI343

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1

1 4

IBI354

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 5

RC118

RRemeGen Co., Ltd.

Phase 2

1 6

Mfolfox

Arcus Biosciences

Phase 1

1 7

SG1906

HHangzhou Sumgen Biotech Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05857332

Clinical

Trials by Indication[1]

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT05857332·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SG1906. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SG1906 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SG1906. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Sumgen Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHangzhou Sumgen Biotech Co., Ltd.

SG1906

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News